WIXOM, Mich.—Rockwell Medical has appointed Iain Macdougall, BSc(Hons), MD, FRCP, to its scientific advisory board (SAB).
Rockwell's SAB currently advises the company on clinical development for its investigational continuous iron-maintenance drug Soluble Ferric Pyrophosphate (SFP), currently in late stage FDA clinical development.
"We are especially pleased to have Dr. Macdougall join our SAB, as he brings a wealth of clinical trial experience in the field of iron supplementation and ESA therapy,” said Robert L. Chioini, chairman, CEO and president of Rockwell. “We are confident that his input will be a great benefit to the SFP clinical development program as we move into phase III studies this year."
Since 1996, Macdougall has been a consultant nephrologist and honorary senior lecturer at King's College Hospital, London. His major research interests are in the field of renal anemia.
Macdougall has led numerous phase I, II and III clinical trials of oral iron, intravenous iron, and ESAs including erythropoietin, darbepoetin, C.E.R.A., and Hematide. He has published more than 160 peer-reviewed research publications and has been a member of both U.S. and European anemia guidelines working groups.
"I am delighted to be part of Rockwell's scientific advisory board,” said Macdougall. “I look forward to providing my input in helping to develop this novel iron treatment, which utilizes a unique mode of delivery for iron supplementation in hemodialysis patients."
